Home > Research > Publications & Outputs > Hospitalisation and mortality risk of SARS-COV-...


Text available via DOI:

View graph of relations

Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England

Research output: Contribution to Journal/MagazineJournal articlepeer-review

  • H H Webster
  • T Nyberg
  • M A Sinnathamby
  • N Abdul Aziz
  • N Ferguson
  • G Seghezzo
  • P B Blomquist
  • J Bridgen
  • M Chand
  • N Groves
  • R Myers
  • R Hope
  • E Ashano
  • J Lopez-Bernal
  • D De Angelis
  • G Dabrera
  • A M Presanis
  • S Thelwall
Article number6053
<mark>Journal publication date</mark>13/10/2022
<mark>Journal</mark>Nature Communications
Issue number1
Number of pages6
Publication StatusPublished
<mark>Original language</mark>English


The Omicron variant of SARS-CoV-2 became the globally dominant variant in early 2022. A sub-lineage of the Omicron variant (BA.2) was identified in England in January 2022. Here, we investigated hospitalisation and mortality risks of COVID-19 cases with the Omicron sub-lineage BA.2 (n = 258,875) compared to BA.1 (n = 984,337) in a large cohort study in England. We estimated the risk of hospital attendance, hospital admission or death using multivariable stratified proportional hazards regression models. After adjustment for confounders, BA.2 cases had lower or similar risks of death (HR = 0.80, 95% CI 0.71-0.90), hospital admission (HR = 0.88, 95% CI 0.83-0.94) and any hospital attendance (HR = 0.98, 95% CI 0.95-1.01). These findings that the risk of severe outcomes following infection with BA.2 SARS-CoV-2 was slightly lower or equivalent to the BA.1 sub-lineage can inform public health strategies in countries where BA.2 is spreading.

Bibliographic note

© 2022. Crown.